Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jul 2019 to Jul 2024
ViroLogic to Present at the UBS Global Life Sciences Conference
on September 30, 2004
SOUTH SAN FRANCISCO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- ViroLogic,
Inc. (NASDAQ:VLGC) announced today that Bill Young, CEO and Chairman, is
scheduled to present a corporate overview at the UBS Global Life Sciences
Conference on Thursday, September 30, 2004 at 11:00 a.m. This event will be
held at the Grand Hyatt Hotel in New York City.
To access the live audio broadcast or the subsequent archived recording log on
to http://www.virologic.com/ and go to the investor relations section. The
archived version of the webcast will be available online for one month.
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious viral diseases such as AIDS and hepatitis. The Company's
products are designed to help doctors optimize treatment regimens that lead to
better patient outcomes and reduced costs. ViroLogic's technology is also being
used by numerous biopharmaceutical companies to develop new and improved
anti-viral therapeutics and vaccines targeted at emerging drug-resistant
viruses. More information about the Company and its technology can be found on
its website at http://www.virologic.com/.
Certain statements in this press release are forward-looking. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to, the
timing of pharmaceutical company clinical trials, risks related to our pending
merger with ACLARA BioSciences, Inc. (ACLARA), including the risk that the
closing conditions of the merger may not be satisfied and the merger may not be
completed, and costs related to the proposed merger may adversely impact
ViroLogic's financial performance, the risks that the Company's products may
not perform, whether ViroLogic successfully introduces new products, risks
related to the implementation of the Company's distribution agreement with a
major national laboratory, whether others introduce competitive products, the
risk that the Company's products for patient testing may not continue to be
accepted or that increased demand from drug development partners may not
develop as anticipated, the risk that gross margins may not increase as
expected, whether payors will authorize reimbursement for its products, whether
the FDA or any other agency will decide to regulate ViroLogic's products or
services, whether the Company will encounter problems or delays in automating
its processes, whether intellectual property underlying the Company's
PhenoSense(TM) technology is adequate, whether licenses to third party
technology will be available, whether ViroLogic is able to build brand loyalty
and expand revenues, and whether ViroLogic will be able to raise sufficient
capital when required. For a discussion of other factors that may cause
ViroLogic's actual events to differ from those projected, please refer to the
Company's most recent annual report on Form 10-K, quarterly reports on Form
10-Q, and the preliminary Joint Proxy/Prospectus related to the proposed merger
with ACLARA, as well as other subsequent filings with the Securities and
Exchange Commission.
DATASOURCE: ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
Web site: http://www.virologic.com/